The scientist’s investigation covers issues in Oncolytic virus, Adenoviridae, Cancer research, Oncolytic adenovirus and Genetic enhancement. Virus and Virology are closely tied to his Oncolytic virus research. His Adenoviridae research is multidisciplinary, relying on both Gene expression and Gene delivery.
His studies deal with areas such as Genetics, Germline mutation and Immunology as well as Cancer research. His research investigates the connection between Immunology and topics such as Cancer that intersect with problems in Disease and Gastroenterology. His Genetic enhancement research is multidisciplinary, incorporating perspectives in Receptor, Ovarian cancer and Virotherapy.
Oncolytic virus, Cancer research, Oncolytic adenovirus, Cancer and Virology are his primary areas of study. His research integrates issues of Adenoviridae, Genetic enhancement and Immunotherapy in his study of Oncolytic virus. His Cancer research study integrates concerns from other disciplines, such as Tumor necrosis factor alpha, Cytokine, Cancer cell, Pathology and Viral vector.
His Oncolytic adenovirus research includes elements of Tumor microenvironment, Cancer immunotherapy, Cell killing and Virotherapy. His biological study spans a wide range of topics, including Relative risk and Lung cancer, Oncology. His study looks at the intersection of Virology and topics like In vivo with In vitro.
His main research concerns Cancer research, Oncolytic adenovirus, Oncolytic virus, Cancer and Internal medicine. Akseli Hemminki has included themes like Tumor necrosis factor alpha, T cell, Cytokine and Immunotherapy in his Cancer research study. Oncolytic adenovirus is the subject of his research, which falls under Immune system.
His research on Oncolytic virus concerns the broader Virus. His work on Prostate cancer as part of general Cancer research is often related to Cancer of unknown primary, thus linking different fields of science. As a part of the same scientific study, Akseli Hemminki usually deals with the Internal medicine, concentrating on Oncology and frequently concerns with Melanoma, Risk factor, Lymphoma, Cancer registry and Squamous cell skin cancer.
His primary areas of study are Oncolytic adenovirus, Cancer research, Oncolytic virus, Cancer and Tumor microenvironment. Part of his project on Oncolytic adenovirus includes research on Immune system and Immunology. He interconnects T cell and Immunotherapy in the investigation of issues within Cancer research.
His Oncolytic virus research incorporates elements of Genetic enhancement and Pattern recognition receptor. His Cancer research is multidisciplinary, relying on both Melanoma and Oncology. His Tumor microenvironment study combines topics from a wide range of disciplines, such as Ex vivo, Tumor-infiltrating lymphocytes, Virus and Virotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
A Hemminki;D Markie;I Tomlinson;E Avizienyte.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu;Pirkko-Liisa Kellokumpu-Lehtinen;Petri Bono;Tuomo Alanko.
The New England Journal of Medicine (2006)
Incidence of Hereditary Nonpolyposis Colorectal Cancer and the Feasibility of Molecular Screening for the Disease
L A Aaltonen;R Salovaara;P Kristo;F Canzian.
The New England Journal of Medicine (1998)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
Tyler J Curiel;Shuang Wei;Haidong Dong;Xavier Alvarez.
Nature Medicine (2003)
Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis
A Hemminki;I Tomlinson;D Markie;H Järvinen.
Nature Genetics (1997)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli.
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Akseli Hemminki;Akseli Hemminki;Jukka–Pekka Mecklin;Heikki Järvinen;Lauri A. Aaltonen.
Patterns of metastasis in colon and rectal cancer
Matias Riihimäki;Matias Riihimäki;Akseli Hemminki;Jan Sundquist;Kari Hemminki;Kari Hemminki.
Scientific Reports (2016)
Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer.
A Hemminki;P Peltomäki;J P Mecklin;H Järvinen.
Nature Genetics (1994)
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
Hongjie Wang;Hongjie Wang;Zong Yi Li;Ying Liu;Jonas Persson.
Nature Medicine (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: